Biotron(OTC) BITRF

Market Cap$115.59M

Since IPO (2013)-70%

5 Year+22%

1 Year+219%

1 Month+3,092%

$0.04

+0.00%

+0.00Today

Biotron last closing stock price
Metric	Price	Date
Last close	USD 0.04	2026-09-25

Biotron stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2,666.67%	USD 0.00	2026-09-18
1 month	+3,092.31%	USD 0.00	2026-08-19
3 month	+1,975%	USD 0.00	2026-06-15
Year to date	+266.45%	USD 0.01	2025-12-31
1 year	+219.23%	USD 0.01	2025-08-21
3 year	+89.5%	USD 0.02	2023-09-22
5 year	+22.06%	USD 0.03	2021-09-14
Since inception	-70.36%	USD 0.14	2013-03-25

Biotron Financials at a Glance

Market Cap

$115.59M

Revenue (TTM)

A$2.34M

Net Income (TTM)

-A$1.84M

EPS (TTM)

-$0.00

P/E Ratio

-69.17

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$0.04

Volume

1,000

Open

$0.04

Price

$0.04

Volume

1,000

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

Feb 26, 2026

Dividend

$0.00

Beta (Volatility)

0.63 (Low)

Price

$0.04

Volume

1,000

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.00 - $0.10

Estimated Earnings Date

Feb 26, 2026

BITRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biotron

Biotron Limited is an Australian biotechnology firm dedicated to developing small-molecule compounds aimed at combating various viral infections. The company's lead antiviral agent, BIT225, is currently in Phase II clinical trials targeting SARS-CoV-2, HIV-1, and hepatitis C virus infections.

Products and Services

BIT225, an antiviral agent in clinical trials
Research and development of small-molecule compounds
Focus on viral infection treatments

Growth Outlook

BIT225 shows promise in treating multiple viral infections
Ongoing Phase II trials may lead to significant market opportunities
Potential partnerships could enhance research capabilities and funding

Financial Highlights

Recent quarterly revenue of AUD 525,869, indicating growth potential
Cash and cash equivalents of AUD 1,551,730, providing operational stability
Current ratio of 1.94 suggests strong short-term financial health

Biotron Limited operates in the dynamic biotechnology sector, focusing on innovative antiviral solutions. The ongoing clinical trials for BIT225 represent a critical step toward addressing significant health challenges posed by viral infections. The company's financial position, highlighted by a solid cash reserve and a favorable current ratio, supports its ongoing research and development efforts. As the market for antiviral treatments continues to expand, Biotron Limited is well-positioned to capitalize on emerging opportunities.

AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Michelle Miller, PhD

Website

www.biotron.com.au

Headquarters

Sydney, NSW 2000, AU

BITRF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-54.03%

Return on Capital

-65.99%

Return on Assets

-40.61%

Earnings Yield

-1.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$115.59M

Shares Outstanding

2.79B

Volume

1.00K

Avg. Volume

2.33K

Financials (TTM)

Gross Profit

A$2.34M

Operating Income

-A$1.86M

EBITDA

-A$2.25M

Operating Cash Flow

-A$2.34M

Capital Expenditure

-A$3.07K

Free Cash Flow

-A$2.34M

Cash & ST Invst.

A$1.55M

Total Debt

A$0.00

Biotron Performance Analysis

Biotron annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-06-30	AUD 0	N/A
2024	2024-06-30	AUD 0	N/A
2025	2025-06-30	AUD 0	N/A
2026	2026-06-30	AUD 0	N/A

Biotron sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-30	N/A
Q4	2025-06-30	-100.0%
Q2	2025-12-31	100.0%
Q4	2026-06-30	N/A

Biotron annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-06-30	AUD -0.00	4.2%
2024	2024-06-30	AUD -0.00	-12.0%
2025	2025-06-30	AUD -0.00	-90.9%
2026	2026-06-30	AUD -0.00	150.0%

Biotron sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-30	125.0%
Q4	2025-06-30	-266.7%
Q2	2025-12-31	100.0%
Q4	2026-06-30	N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

A$525.87K

N/A

Gross Profit

A$525.87K

+1498.9%

Gross Margin

100.00%

N/A

Market Cap

$115.59M

N/A

Market Cap/Employee

$38.53M

N/A

Employees

N/A

Net Income

-A$596.50K

+71.8%

EBITDA

-A$1.03M

+51.6%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

A$1.55M

+294.6%

Total Debt

A$0.00

-100.0%

Accounts Receivable

A$18.00K

N/A

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

-100.0%

Return on Assets

-40.61%

N/A

Return on Invested Capital

-65.99%

N/A

Free Cash Flow

-A$906.98K

-195.0%

Operating Cash Flow

-A$906.98K

-195.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

GRCUGlobal Roundtable Corporation

GRCUGlobal Roundtable Corporation$0.00+0.00%

TSOITherapeutic Solutions International, Inc.

TSOITherapeutic Solutions International, Inc.$0.00+0.00%

DYNTDynatronics Corporation

DYNTDynatronics Corporation$0.04+0.00%

VIRXViracta Therapeutics, Inc.

VIRXViracta Therapeutics, Inc.$0.01+0.00%

BPTSYBiophytis S.A.

BPTSYBiophytis S.A.$0.25+0.00%

PFNDPathfinder Cell Therapy, Inc.

PFNDPathfinder Cell Therapy, Inc.$0.00+0.00%

MCETMultiCell Technologies, Inc.

MCETMultiCell Technologies, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

GLNDGreenland Energy

GLNDGreenland Energy$5.54+3.55%

INTCIntel

INTCIntel$123.00-3.45%

NVDANvidia

NVDANvidia$225.07+0.22%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.94-3.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.87+3.90%

ONDSOndas

ONDSOndas$7.64+0.53%

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF

SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF$32.43-3.57%

Questions About BITRF

What is the current price of Biotron?

Biotron is trading at $0.04 per share.

What is the 52-week range for Biotron?

Over the past 52 weeks, Biotron has traded between $0.00 and $0.10.

How much debt does Biotron have?

As of the most recent reporting period, Biotron reported total debt of A$0.00.

How much cash does Biotron have on hand?

Biotron reported A$1.08M in cash and cash equivalents in its most recent financial results.

What is Biotron’s dividend yield?

Biotron does not currently have a dividend yield.

Biotron(OTC) BITRF

Biotron Financials at a Glance

BITRF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Biotron

BITRF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Biotron Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About BITRF

What is the current price of Biotron?

What is the 52-week range for Biotron?

How much debt does Biotron have?

How much cash does Biotron have on hand?

What is Biotron’s dividend yield?

Premium Investing Services